[HTML][HTML] Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts
L Petropoulou-Vathi, A Simitsi, PE Valkimadi… - npj Parkinson's …, 2022 - nature.com
Despite several advances in the field, pharmacodynamic outcome measures reflective of
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts.
L Petropoulou-Vathi, A Simitsi, PE Valkimadi… - NPJ Parkinson's …, 2022 - europepmc.org
Despite several advances in the field, pharmacodynamic outcome measures reflective of
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts
L Petropoulou-Vathi, A Simitsi, PE Valkimadi… - bioRxiv, 2021 - biorxiv.org
Despite several advances in the field, pharmacodynamic outcome measures reflective of
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
[HTML][HTML] Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts
L Petropoulou-Vathi, A Simitsi, PE Valkimadi… - NPJ Parkinson's …, 2022 - ncbi.nlm.nih.gov
Despite several advances in the field, pharmacodynamic outcome measures reflective of
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts
L Petropoulou-Vathi, A Simitsi… - NPJ Parkinson's …, 2022 - search.proquest.com
Despite several advances in the field, pharmacodynamic outcome measures reflective of
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts
L Petropoulou-Vathi, A Simitsi… - NPJ Parkinson's …, 2022 - pubmed.ncbi.nlm.nih.gov
Despite several advances in the field, pharmacodynamic outcome measures reflective of
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
[PDF][PDF] Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts
L Petropoulou-Vathia, A Simitsib, PE Valkimadia… - scholar.archive.org
Despite several advances in the field, pharmacodynamic outcome measures reflective of
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts.
L Petropoulou-Vathi, A Simitsi… - NPJ Parkinson's …, 2022 - search.ebscohost.com
Despite several advances in the field, pharmacodynamic outcome measures reflective of
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts
L Petropoulou-Vathi, A Simitsi, P Valkimadi, M Kedariti… - 2021 - europepmc.org
Despite several advances in the field, pharmacodynamic outcome measures reflective of
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …
LRRK2 kinase activity in clinical biofluids remain urgently needed. A variety of targets and …